Mira Tout

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

P. Feugier, S. Leprêtre, R. Letestu, 2018, Haematologica.

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

S. Leprêtre, V. Gouilleux-Gruart, A. Delmer, 2017, Clinical Pharmacokinetics.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

G. Salles, O. Casasnovas, P. Feugier, 2017, Blood.

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

N. Baroukh, C. Borg, O. Bouché, 2017, BMC Cancer.

Gota et al. on their article “the pharmacokinetics of Reditux™, a biosimilar of rituximab”

G. Paintaud, G. Cartron, D. Ternant, 2016, Cancer Chemotherapy and Pharmacology.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

G. Salles, O. Casasnovas, P. Feugier, 2017, Blood.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study

O. Casasnovas, P. Feugier, C. Haioun, 2020 .